Akademisyen
ŞÜKRİYE GÜNİZ KÜÇÜKGÜZEL
PROFESÖR
FENERBAHÇE ÜNİVERSİTESİ ECZACILIK FAKÜLTESİ ECZACILIK MESLEK BİLİMLERİ BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Farmasotik Kimya
Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.
- Makale 108
- Proje 0
- Kitap 6
- Bildiri 151
- Patent 0
- Sanatsal 0
Scopus (SJR)
Q1
19
Q2
37
Q3
20
Q4
3
WoS (JCR)
Q1
9
Q2
24
Q3
28
Q4
16
TR Index
14
makale
Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.
Üst %1 makale
0
Üst %10 makale
12
Ort. yüzdelik
71.8%
Üst %1 payı
0.0%
Üst %10 payı
15.2%
Makaleler
YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.
Makale listesi
- 2026 2‐Pyrazoline‐5‐One Derivative Suppresses Cell Proliferation and Induces Apoptosis With Upregulation of Bax in Breast Cancer Cells YÖKSİS SJR Q2 JCR Q2 OpenAlex 57.2%
- 2026 Investigation of the printability of ethyl 2‐[4‐(1,3,4‐oxadiazol‐2(3H)‐thion‐5‐yl)phenylhydrazono]‐3‐oxobutyrate on coated and uncoated papers YÖKSİS SJR Q2 JCR Q2 OpenAlex 2.1%
- 2026 Ibuprofen and nimesulide derivatives selectively induce apoptosis in HER2-positive breast cancer via inhibition of the PLA₂–COX-2–NF-κB pathway YÖKSİS SJR Q2 JCR Q3 OpenAlex 36.8%
- 2026 New Diclofenac Hydrazones: Design, Synthesis, In Silico Studies and Anticancer Evaluation against Breast Cancer YÖKSİS SJR Q2 JCR Q2 OpenAlex 63.6%
- 2026 Novel hydrazide-hydrazone derivatives containing f lurbiprofen 1,2,4-triazole as anticancer agents: design, synthesis and biological evaluation YÖKSİS SJR Q3 JCR Q4 OpenAlex 1.4%
- 2026 Synthesis, characterization, biological evaluation, and molecular modeling of novel nimesulide urea derivatives as potential MetAP2 inhibitors YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 93.3%
- 2025 Biological Activities of Etodolac‐Based Hydrazone, Thiazolidinone and Triazole Derivatives on Breast Cancer Cell Lines MCF‐7 and MDA‐MB‐231 YÖKSİS SJR Q2 JCR Q2 OpenAlex 84.9%
- 2025 Investigation of novel nimesulide derivatives against breast cancer YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 90.6%
- 2025 Design and synthesis of thiosemicarbazides and 1,2,4-triazoles derived from ibuprofen as potential MetAP (type II) inhibitors YÖKSİS SJR Q1 JCR Q1 OpenAlex 78.2%
- 2024 Evaluation of Hydrazide-hydrazone and 4-thiazolidinone Derivatives of Etodolac as Potential Anticancer Agents in Leukemia Cells YÖKSİS SJR Q3 JCR Q4 OpenAlex 62.3%
- 2024 Synthesis of new 4-aminobenzoic acid (PABA) hydrazide-hydrazone/sulfonate hybrids and antimicrobial evaluation with ascorbic acid/salicylic acid/ N -acetyl cysteine combinations YÖKSİS SJR Q4 JCR Q3 OpenAlex 67.9%
- 2023 Synthesis and Evaluation of Novel Metacetamol Derivatives with Hydrazone Moiety as Anticancer and Antimicrobial Agents YÖKSİS SJR Q2 JCR Q3 OpenAlex 66.2%
- 2023 Synthesis, antimicrobial properties and in silico studies of aryloxyacetic acid derivatives with hydrazone or thiazolidine-4-one scaffold YÖKSİS SJR Q2 JCR Q2 OpenAlex 55.7%
- 2023 Synthesis and investigation of cytotoxic effects of compounds derived from flurbiprofen YÖKSİS SJR Q2 JCR Q2 OpenAlex 49.2%
- 2023 A Novel PEtOx‐Based Nanogel Targeting Prostate Cancer Cells for Drug Delivery YÖKSİS SJR Q1 JCR Q2 OpenAlex 50.2%
- 2023 Synthesis and biological evaluation of new 4-thiazolidinone derivatives of flurbiprofen YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 42.6%
- 2023 In silico studies and in vitro microsomal metabolism of potent MetAP2 inhibitor and in vivo tumor suppressor for prostate cancer: A thioether-triazole hybrid YÖKSİS TR Index OpenAlex 64.4%
- 2022 Synthesis, antimicrobial evaluation and molecular modeling studies of novel thiosemicarbazides/semicarbazides derived from p-aminobenzoic acid YÖKSİS SJR Q2 JCR Q2 OpenAlex 80.1%
- 2022 Synthesis, Antimicrobial Evaluation, and Molecular Modeling Studies of New Thiosemicarbazide-Triazole Hybrid Derivatives of (S)-Naproxen. YÖKSİS SJR Q2 JCR Q3 OpenAlex 74.9%
- 2022 Synthesis, characterization, in vitro and in vivo anticancer activity studies of new (S)-Naproxen thiosemicarbazide/1,2,4-triazole derivatives YÖKSİS SJR Q2 JCR Q2 OpenAlex 78.7%